Bioinformatics, Computational Informatics, and Modeling Approaches to the Design of mRNA COVID-19 Vaccine Candidates

Area of Science:

• Bioinformatics and Immunoinformatics
• Vaccine Development
• Molecular Biology

Background:

• Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants pose a significant global health threat.
• The spike glycoprotein is crucial for SARS-CoV-2 entry into host cells and a primary target for vaccines.
• Specific SARS-CoV-2 variants, including Delta and Omicron, have shown high prevalence in African countries.

Purpose of the Study:

• To design a multi-epitope mRNA vaccine targeting spike glycoproteins of SARS-CoV-2 variants circulating in Africa.
• To utilize bioinformatics and immunoinformatics tools for predicting and selecting effective T- and B-lymphocyte epitopes.
• To evaluate the potential immunogenicity and population coverage of the developed vaccine candidate.

Main Methods:

• Bioinformatics and immunoinformatics tools were employed to predict T- and B-lymphocyte epitopes.
• Epitopes were rigorously evaluated for their potential to elicit a sustained immune response.
• The vaccine construct included seven epitopes, an adjuvant, an MHC I-targeting domain, a signal peptide, and linkers.

Main Results:

• A multi-epitope vaccine candidate was designed with a molecular weight of 223.1 kDa, exhibiting antigenic, non-allergenic, non-toxic, thermostable, and hydrophilic properties.
• The vaccine candidate demonstrated good population coverage across African regions, with East Africa showing the highest coverage (80.44%).
• Molecular docking revealed high binding affinity to TLR4, indicating potential for stimulating innate and adaptive immunity.

Conclusions:

• The developed multi-epitope mRNA vaccine candidate shows promise for targeting SARS-CoV-2 variants in Africa.
• The vaccine's design incorporates features for high immunogenicity and broad population coverage.
• Further research and clinical trials are warranted to validate the efficacy of this vaccine candidate.